アンドロゲン乱用のためのハームリダクション介入の効果：対照試験

Androgen abuse for performance- and image-enhancement is increasing despite preventive efforts, yet no controlled trials have evaluated harm reduction strategies. This trial assessed whether a harm reduction intervention could reduce androgen abuse in males.

Historically controlled trial.

This one-year prospective intervention study included 99 male amateur athletes planning to start an androgen cycle. Outcomes were compared to a historical cohort study (n = 100) from our research group receiving no intervention. The intervention comprised individualized counseling and medical assessments. Primary outcomes included cumulative androgen dose, cycle duration, and weekly dosage. Secondary outcome included within-participant deviation from planned abuse.

Baseline characteristics were largely comparable, although intervention participants reported slightly more weekly training time and lower intended cumulative cycle dose. Twelve percent refrained from initiating a cycle due to the intervention. The mean cumulative androgen dose was 13,087 (95% CI -16,564 to -9,609) mg lower in the intervention group (6,323 ± 5,229 mg) compared to controls (19,410 ± 16,497 mg). Within-person differences showed an average reduction of 8,729 (95% CI -11,297 to -6,287) mg in the intervention group compared to controls. Multivariable regression confirmed the interventions' effect was independent of baseline differences. No significant enabling effect was observed.

This is the first controlled study to demonstrate that a harm reduction intervention can reduce androgen exposure among men planning to abuse androgens. These findings support harm reduction as a promising strategy to mitigate health risks associated with androgen abuse. Future studies should confirm generalizability and monitor for potential enabling effects.